130 related articles for article (PubMed ID: 22842680)
1. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis.
Ku JH; Lerner SP
Curr Opin Urol; 2012 Sep; 22(5):405-14. PubMed ID: 22842680
[TBL] [Abstract][Full Text] [Related]
2. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
3. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
4. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
5. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
Sylvester RJ
Int J Urol; 2011 Feb; 18(2):113-20. PubMed ID: 21091799
[TBL] [Abstract][Full Text] [Related]
7. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
8. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
9. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
[TBL] [Abstract][Full Text] [Related]
10. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Saint F
Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
[TBL] [Abstract][Full Text] [Related]
11. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
Andius P; Holmäng S
BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
[TBL] [Abstract][Full Text] [Related]
13. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
[TBL] [Abstract][Full Text] [Related]
14. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
15. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
16. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Palou J; Rodríguez O; Segarra J; Rosales A
J Urol; 2006 Jul; 176(1):407; author reply 407-8. PubMed ID: 16753451
[No Abstract] [Full Text] [Related]
17. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.
Kulkarni GS; Hakenberg OW; Gschwend JE; Thalmann G; Kassouf W; Kamat A; Zlotta A
Eur Urol; 2010 Jan; 57(1):60-70. PubMed ID: 19740595
[TBL] [Abstract][Full Text] [Related]
18. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
[TBL] [Abstract][Full Text] [Related]
19. Developments in intravesical therapy for non-muscle-invasive bladder cancer.
Lammers RJ; Witjes JA
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1903-16. PubMed ID: 21110757
[TBL] [Abstract][Full Text] [Related]
20. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]